Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Ongericimab Biologics Sequence Review Report 2026: PCSK9 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ongericimab, an antibody targeting PCSK9.
6 min read
Odesivimab Biologics Sequence Review Report 2026: Zaire Ebolavirus Glycoprotein Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Odesivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.
6 min read
Docaravimab Biologics Sequence Review Report 2026: Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-III Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Docaravimab, an antibody targeting Rabies Virus Strain ERA Glycoprotein Ectodomain Epitope G-III.
6 min read
Datopotamab Biologics Sequence Review Report 2026: TROP2 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Datopotamab, an antibody targeting TROP2.
6 min read
Recaticimab Biologics Sequence Review Report 2026: PCSK9 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Recaticimab, an antibody targeting PCSK9.
6 min read
Pucotenlimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pucotenlimab, an antibody targeting PD-1.
6 min read
Masavibart Biologics Sequence Review Report 2026: SARS-CoV-2 Spike RBD Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Masavibart, an antibody targeting SARS-CoV-2 Spike RBD.
6 min read
Finotonlimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Finotonlimab, an antibody targeting PD-1.
6 min read
Ebdarokimab Biologics Sequence Review Report 2026: IL-12/23p40 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ebdarokimab, an antibody targeting IL-12/23p40.
6 min read
Ansuvimab Biologics Sequence Review Report 2026: Zaire Ebolavirus Glycoprotein Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ansuvimab, an antibody targeting Zaire Ebolavirus Glycoprotein.
6 min read
Xeligekimab Biologics Sequence Review Report 2026: IL-17A Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Xeligekimab, an antibody targeting IL-17A.
6 min read
Tuvonralimab Biologics Sequence Review Report 2026: CTLA-4 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tuvonralimab, an antibody targeting CTLA-4.